Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results

Executive Summary

Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.

You may also be interested in...

Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator

The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.

Minute Insight: Abbott Receives US FDA Clearance For Spinal Cord Stimulator

Abbott announced on 19 December that the US Food and Drug Administration has approved its Eterna spinal cord stimulation system (SCS) for treating chronic pain with low-dose BURSTDR stimulation.

Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain

New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts